Q-omics provides the consensus-scored KRT90P profile across patient tissues and cancer cell-line models. KRT90P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KRT90P is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, KRT90P RNA expression shows 6,499 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, HNSC, and STAD as cancer lineages where KRT90P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT90P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT90P survival associations across molecular data types. KRT90P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT90P RNA expression–survival associations across cancer types. High KRT90P expression shows unfavorable associations in MESO, KICH, BRCA, LUSC and PCPG, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for KRT90P RNA expression.
This table summarizes KRT90P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT90P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT90P shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher KRT90P RNA expression in tumor versus normal tissue (log2 FC = +0.115, t-test p < 0.001).
This table shows molecular features associated with KRT90P in patient tissues and cancer cell lines. In patient samples, KRT90P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
